Compare MTEN & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEN | CNSP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.5M |
| IPO Year | 2022 | 2019 |
| Metric | MTEN | CNSP |
|---|---|---|
| Price | $1.03 | $4.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 228.5K | 3.7K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $1.90 |
| 52 Week High | $9.52 | $10.59 |
| Indicator | MTEN | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 38.04 |
| Support Level | $0.97 | $4.85 |
| Resistance Level | $1.07 | $5.53 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 14.24 | 0.00 |
Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides an extensive product lineup, including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in the automobile, construction machinery, and other manufacturing industries.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.